Royal Bank of Canada Has $104.16 Million Position in Becton, Dickinson and Company $BDX

Royal Bank of Canada boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.8% during the first quarter, Holdings Channel.com reports. The fund owned 662,476 shares of the medical instruments supplier’s stock after acquiring an additional 18,341 shares during the period. Royal Bank of Canada’s holdings in Becton, Dickinson and Company were worth $104,161,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Imprint Wealth LLC acquired a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth $25,000. Steph & Co. raised its stake in Becton, Dickinson and Company by 95.6% in the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 65 shares in the last quarter. SHP Wealth Management acquired a new position in Becton, Dickinson and Company in the fourth quarter valued at about $26,000. Meeder Asset Management Inc. lifted its position in Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 102 shares during the period. Finally, Main Street Group LTD acquired a new stake in Becton, Dickinson and Company during the first quarter worth about $29,000. 86.97% of the stock is currently owned by institutional investors.

Insider Activity at Becton, Dickinson and Company

In other news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the transaction, the executive vice president owned 13,172 shares of the company’s stock, valued at $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 5,189 shares of company stock valued at $765,661. 0.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Barclays raised their target price on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a report on Monday, May 11th. TD Cowen reduced their price target on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating on the stock in a research report on Monday, May 4th. Royal Bank Of Canada set a $175.00 price objective on shares of Becton, Dickinson and Company in a research note on Tuesday, April 14th. The Goldman Sachs Group lowered their price objective on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research report on Wednesday, May 27th. Finally, Piper Sandler cut their target price on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a research note on Friday, April 17th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Becton, Dickinson and Company presently has an average rating of “Hold” and a consensus price target of $180.93.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $166.19 on Friday. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. The stock has a market cap of $45.79 billion, a PE ratio of 42.07, a P/E/G ratio of 11.79 and a beta of 0.21. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35. The business’s 50-day moving average price is $151.85 and its two-hundred day moving average price is $163.64.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.67 billion. During the same quarter in the prior year, the business earned $3.35 earnings per share. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, analysts expect that Becton, Dickinson and Company will post 12.53 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 106.33%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.